The UK medicines regulator has given approval for an experimental vaccine to be tested on healthy adults.
2d
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
ATTR-CM treatment options narrowed after AstraZeneca and Ionis revealed their gene-silencing drug Wainua (eplontersen) failed ...
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...
AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis , unexpectedly failed a pivotal heart-disease trial, ...
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a ...
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive ...
AstraZeneca has opened a new chapter in hypertension treatment after the U.S. Food and Drug Administration approved Baxfendy ...
The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...
Health Minister Budi Gunadi Sadikin sets a target for Indonesia to domestically manufacture all 15 vaccine antigens used in ...
The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective. AstraZeneca and Ionis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results